
|Articles|December 1, 2008
- ONCOLOGY Vol 22 No 14
- Volume 22
- Issue 14
FDA Approves New Imaging System to Enhance Cervical Cancer Detection
BD Diagnostics recently announced that it received US Food and Drug Administration (FDA) Premarket Approval for the BD FocalPoint GS Imaging System.
Advertisement
BD Diagnostics recently announced that it received US Food and Drug Administration (FDA) Premarket Approval for the BD FocalPoint GS Imaging System. This innovative new system is designed to enhance cervical cancer screening for cytology laboratories using the BD SurePath Pap test slides to detect evidence of squamous carcinoma, adenocarcinoma and their usual precursor conditions.
Articles in this issue
over 17 years ago
The Absent-Minded Professor: An Unusual Complication of Melanomaover 17 years ago
Inflammatory Breast Cancer: A Complex Diseaseover 17 years ago
Defining the IBC Phenotypeover 17 years ago
Acupunctureover 17 years ago
Two Orphan Drug Designations Granted for Reviroc in NHLover 17 years ago
NDA Submitted for Trabectedin to Treat Relapsed Ovarian Cancerover 17 years ago
FDA Considers Update for Tanning Bed LabelsAdvertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Accepts NDA for Mezigdomide Combo in R/R Multiple Myeloma
2
Dostarlimab Yields Sustained Complete Responses in dMMR/MSI-H Rectal Cancer
3
ADCs in the Frontline: Evolving Approaches in Metastatic TNBC
4
Risvutatug Rezetecan Improves Overall Survival in Relapsed SCLC Trial
5



























































